These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 36795354

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. RNA-targeting and gene editing therapies for transthyretin amyloidosis.
    Aimo A, Castiglione V, Rapezzi C, Franzini M, Panichella G, Vergaro G, Gillmore J, Fontana M, Passino C, Emdin M.
    Nat Rev Cardiol; 2022 Oct; 19(10):655-667. PubMed ID: 35322226
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials.
    Tomasoni D, Bonfioli GB, Aimo A, Adamo M, Canepa M, Inciardi RM, Lombardi CM, Nardi M, Pagnesi M, Riccardi M, Vergaro G, Vizzardi E, Emdin M, Metra M.
    Front Cardiovasc Med; 2023 Oct; 10():1154594. PubMed ID: 37288260
    [Abstract] [Full Text] [Related]

  • 5. Recent Advances in Oligonucleotide-Based Therapy for Transthyretin Amyloidosis: Clinical Impact and Future Prospects.
    Hayashi Y, Jono H.
    Biol Pharm Bull; 2018 Oct; 41(12):1737-1744. PubMed ID: 30504675
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Advances in the treatment of hereditary transthyretin amyloidosis: A review.
    Gertz MA, Mauermann ML, Grogan M, Coelho T.
    Brain Behav; 2019 Sep; 9(9):e01371. PubMed ID: 31368669
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Overview of Current and Emerging Therapies for Amyloid Transthyretin Cardiomyopathy.
    Maurer MS.
    Am J Cardiol; 2022 Dec; 185 Suppl 1():S23-S34. PubMed ID: 36371281
    [Abstract] [Full Text] [Related]

  • 15. Advances in the treatment of transthyretin cardiac amyloidosis: Current and emerging therapies.
    Warner AL.
    Pharmacotherapy; 2021 Dec; 41(12):1081-1091. PubMed ID: 34669976
    [Abstract] [Full Text] [Related]

  • 16. Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system.
    Conceição I.
    Clin Auton Res; 2019 Sep; 29(Suppl 1):11-17. PubMed ID: 31399774
    [Abstract] [Full Text] [Related]

  • 17. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.
    Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, Seitzer J, O'Connell D, Walsh KR, Wood K, Phillips J, Xu Y, Amaral A, Boyd AP, Cehelsky JE, McKee MD, Schiermeier A, Harari O, Murphy A, Kyratsous CA, Zambrowicz B, Soltys R, Gutstein DE, Leonard J, Sepp-Lorenzino L, Lebwohl D.
    N Engl J Med; 2021 Aug 05; 385(6):493-502. PubMed ID: 34215024
    [Abstract] [Full Text] [Related]

  • 18. Treatment of cardiac transthyretin amyloidosis: an update.
    Emdin M, Aimo A, Rapezzi C, Fontana M, Perfetto F, Seferović PM, Barison A, Castiglione V, Vergaro G, Giannoni A, Passino C, Merlini G.
    Eur Heart J; 2019 Dec 01; 40(45):3699-3706. PubMed ID: 31111153
    [Abstract] [Full Text] [Related]

  • 19. Treatment of transthyretin cardiac amyloidosis.
    Bampatsias D, Wardhere A, Maurer MS.
    Curr Opin Cardiol; 2024 Sep 01; 39(5):407-416. PubMed ID: 38652263
    [Abstract] [Full Text] [Related]

  • 20. Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis.
    Benson MD, Dasgupta NR, Monia BP.
    Neurodegener Dis Manag; 2019 Feb 01; 9(1):25-30. PubMed ID: 30561247
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.